Vigabatrin: Completed Phase IIb enrollment

Catalyst completed enrollment of about 210 cocaine-dependent patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating vigabatrin. Patients will receive twice-daily 1.5 g oral vigabatrin or placebo for 9 weeks. NIH's National Institute on Drug Abuse (NIDA) and the Veteran's Administration Cooperative Studies Program are collaborating with Catalyst for the trial. NIDA will cover most of the site costs for the trial, while the VA will handle site monitoring and data management. ...